Latest Immunotherapy News

Imugene Limited and JW Therapeutics have launched a strategic collaboration to combine oncolytic virus and CAR-T cell therapies, aiming to tackle refractory solid tumors through a pioneering 'mark and kill' approach.

Immutep Limited’s Phase II EFTISARC-NEO trial reveals a novel immunotherapy combo delivering a striking 51.5% tumour response in soft tissue sarcoma patients, alongside robust immune activation signals.

Radiopharm Theranostics has successfully enrolled the second cohort in its Phase 1 trial of 177Lu-RAD204, with the Data Safety Monitoring Committee greenlighting a dose increase to 90mCi for the third cohort. Early results show promising tumor targeting and safety in multiple advanced cancers.

Immutep Limited has received a significant A$4.6 million cash payment from the French government’s R&D tax incentive scheme, supporting its ongoing immunotherapy clinical programs.

Imugene Limited reports an 81% overall response rate in its azer-cel CAR T-cell therapy trial for difficult lymphomas, alongside a $25 million capital raise that extends its cash runway to mid-2027.

Immuron Limited reports progress on its IMM-529 FDA application and a delay in Travelan® clinical trial results due to a U.S. government shutdown, with key data now expected in late November.

Percheron Therapeutics reports encouraging phase I clinical results for HMBD-002, confirming safety and early efficacy signals, while gearing up for a multi-arm phase II trial in 2026.

Immutep Limited reports strong progress in its Phase III lung cancer trial with over 170 patients enrolled, alongside positive FDA feedback and a robust cash position supporting ongoing development.

AdAlta Limited has completed the final share issuance under its Investment Agreement with the Meurs Group, securing the full $700,000 investment that bolstered its cellular immunotherapy development.

AdAlta Limited has made significant progress in its 'East to West' cellular immunotherapy strategy, advancing licensing negotiations for its first CAR-T product and raising $1.6 million through placements to bolster its financial position.

Arovella Therapeutics has secured encouraging feedback from the US FDA on reagent testing for its CAR-iNKT cell therapy, setting the stage for an IND filing this quarter and clinical trials in early 2026.

AdAlta Limited has fully repaid its remaining NLSC investment in cash, ending its obligation to issue further shares and positioning itself for private capital raises to advance its CAR-T therapies.